This page outlines which patients and clinical scenarios may benefit from the bioresorbable MitraMag implant, providing a roadmap to help clinicians identify optimal candidates for this innovative therapy.
Target Patient Groups & Indications
Infective Endocarditis
Patients with infective endocarditis specifically affecting the mitral valve structure.
Drug Abuse History
Patients with a history of drug abuse where long-term reduction of foreign-body burden is clinically desirable.
Adolescents
Growing patients who benefit from a biodegradable implant that supports healing and is gradually resorbed.
Rheumatic Heart Disease
Clinical scenarios involving rheumatic heart disease requiring surgical intervention.
Mitral Valve Repair
Patients requiring surgical mitral valve repair rather than replacement (about 90% of eligible cases).
High Superinfection Risk
Patients with a heightened risk of superinfection or recurrent infection following surgery.
Biodegradable Support
Patients benefiting from a biodegradable implant focused on supporting short-term healing.
Reduced Burden
Scenarios where minimizing long-term foreign materials is a priority for clinical recovery.
The integration of the MitraMag provides clinicians with a powerful tool to minimize long-term implant complications while actively preventing re-infection. This approach supports natural tissue healing and growth, offering a superior clinical outcome for vulnerable patient populations requiring sustainable mitral repair.